![Ontario Institute for Cancer Research logo](https://facit.ca/wp-content/uploads/2021/11/OICR.png)
OICR (Cellax)
oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Cellax is a self-assembling nanoparticle drug-polymer conjugate that selectively targets tumour cells for enhanced cancer treatment with fewer side effects.